Ethylene Oxide Residual Testing for Medical Devices: Standards, Methods, and Limits

Ethylene oxide (EO) sterilization is the method of choice for heat- and moisture-sensitive medical devices, but toxic residues of EO and its by-product ethylene chlorohydrin (ECH) must be strictly quantified before products are released to patients. This article explains the applicable standards, tolerable limits, sample types, extraction procedures, and gas chromatography-based test methods used for determining ethylene oxide residuals in medical devices in accordance with ISO 10993-7, GB/T 16886.7, and related specifications.

Technical Overview

Ethylene oxide (EO, also written as EtO) is one of the most widely used sterilization agents for medical devices that cannot withstand high-temperature steam or radiation processes. Its strong penetrating capability allows it to sterilize complex devices with lumens, polymer components, and breathable packaging at relatively low temperatures, typically between 37 °C and 63 °C. However, EO is a reactive alkylating agent that is toxic, irritating, and classified as a human carcinogen by international cancer research agencies. During sterilization and subsequent storage, EO can also react with water and chloride ions to form ethylene chlorohydrin (ECH, 2-chloroethanol) and ethylene glycol (EG). Because these chemical species can leach from the device into the patient during clinical use, residual levels must be measured and demonstrated to be below biologically safe limits before product release.

Determination of EO residuals is a mandatory element of ethylene oxide sterilization validation and routine control, as required by ISO 11135 and its Chinese counterpart GB 18279.1. The biological evaluation of these residues is governed by ISO 10993-7 (Biological evaluation of medical devices – Part 7: Ethylene oxide sterilization residuals), which is adopted in China as GB/T 16886.7. The core analytical technique is gas chromatography, most commonly headspace gas chromatography with flame ionization detection (HS-GC-FID), supported by gas chromatography–mass spectrometry (GC-MS) where higher selectivity or confirmation is required. Accredited third-party laboratories and in-house quality control laboratories worldwide apply these methods for batch release and regulatory submissions.

Residual Species of Concern

• Ethylene oxide (EO): the primary sterilant residue, highly volatile and diffusible through polymers.
• Ethylene chlorohydrin (ECH): a reaction by-product of EO with chloride-containing materials or solutions; more toxic per unit mass than EO.
• Ethylene glycol (EG): a further degradation product of EO; ISO 10993-7 considers EG of comparatively low toxicological concern and does not assign a specific limit, although it may be monitored for information.

Governing Standards and Specifications

• ISO 10993-7:2008: establishes tolerable exposure limits (TELs) and the framework for residual evaluation.
• GB/T 16886.7: the Chinese national standard technically aligned with ISO 10993-7.
• ISO 11135:2014 and GB 18279.1: requirements for development, validation, and routine control of EO sterilization processes, including aeration and release criteria.
• GB/T 14233.1: chemical analysis methods for infusion, transfusion, and injection equipment, including a headspace GC procedure for EO residuals.
• EN ISO 10993-7: the European adoption of the international standard used for CE-related conformity activities.

Testing Samples

Essentially any medical device sterilized with ethylene oxide is a candidate for residual testing. The scope of testing and the applicable exposure category depend on the intended duration of patient contact.

Direct and Invasive Contact Devices

Infusion sets, syringes, intravenous cannulae, urinary and intravascular catheters, hemodialyzers, blood oxygenators, extracorporeal circulation tubing, endotracheal tubes, and breathing circuits. These devices deliver residuals directly into the bloodstream or mucosal tissue and are the most safety-critical category.

Surgical and Wound Contact Products

Absorbable and non-absorbable sutures, surgical meshes, wound dressings, absorbent pads, adhesive bandages, drapes, and packs. Polymeric and cellulose-based materials tend to absorb EO strongly, and dense packaging can slow dissipation, so these products often define the worst case for aeration studies.

Devices with Polymer, Composite, or Electronic Components

Laparoscopic and endoscopic instruments with plastic parts, powered surgical accessories, electronic sensors, diagnostic cartridges, and laboratory-use sterile consumables. These devices are frequently EO-sterilized precisely because heat and moisture would damage their components.

Sampling and Transport Considerations

Because EO is highly volatile, sample integrity is critical. Samples must remain sealed in their original primary packaging until analysis, be transported without unnecessary temperature elevation, and be extracted or transferred to sealed headspace vials promptly after opening. Test plans should sample from worst-case locations within the sterilization load, typically the densest pallet center and most impermeable packaging, at the earliest allowable release time point.

Testing Items

The standard test panel covers the residual sterilant and its principal reaction by-product, with results expressed either as mass per device (mg/device) or mass per mass of material (µg/g), depending on the calculation model required by ISO 10993-7.

• Ethylene oxide (EO) residual content.
• Ethylene chlorohydrin (ECH) residual content.
• Ethylene glycol (EG) content (optional, informational).
• Calculated patient-delivered dose for comparison against tolerable exposure limits.

Tolerable Exposure Limits According to ISO 10993-7

• Limited exposure devices (patient contact 24 h or less): maximum 4 mg EO and 9 mg ECH per device.
• Prolonged exposure devices (contact from 24 h up to 30 days): maximum 2 mg EO and 3 mg ECH per device.
• Long-term exposure devices (contact 30 days or more): limits are expressed as average daily doses, commonly 0.1 mg/day for EO and 2 mg/day for ECH, calculated over the total contact duration.

For devices used in multiple patients or released for use after a defined aeration quarantine period, the delivered dose must be evaluated at the point of earliest patient contact, not at a later storage time when residuals have already declined.

Testing Methods

The analytical workflow consists of three stages: sample extraction, chromatographic separation and detection, and quantitative evaluation against the limits. All work is performed in controlled laboratory environments by qualified personnel using validated instruments and certified reference standards.

Sample Extraction Procedures

• Simulated-use extraction: the device is extracted in a defined volume of water under conditions that simulate clinical use, typically 37 °C for 24 h. This is the preferred approach for devices that contact the patient through an aqueous medium.
• Exhaustive extraction: the sample is extracted repeatedly with fresh solvent until the amount recovered in a subsequent extraction falls below approximately 10 % of the first, ensuring the total residual burden is captured. This conservative approach suits implants and permanent-contact devices.
• Direct headspace sampling: for volatile EO in suitable matrices, the material is sealed in a headspace vial, equilibrated at an elevated temperature, and the headspace gas is analyzed directly without a separate liquid extraction step.
• Special handling for ECH: because ECH is polar and only semi-volatile, it is generally quantified from aqueous extracts, with chromatographic conditions or derivatization techniques adapted to achieve adequate sensitivity.

Chromatographic Analysis

Headspace gas chromatography with flame ionization detection is the industry-standard technique for EO. An aliquot of equilibrated headspace vapor or extracted solution is injected onto a capillary column, where EO is separated from matrix volatiles and quantified against an external calibration curve prepared from certified EO standards. GC-MS provides confirmatory identification and enhanced selectivity for complex matrices or dispute resolution. Modern systems achieve limits of quantification far below the milligram-level regulatory limits, with automated headspace samplers improving reproducibility and throughput.

Calibration, Validation, and Quality Control

Methods are validated for linearity across the working range, accuracy and recovery from spiked samples, precision (repeatability and intermediate precision), specificity, and limits of detection and quantification. Each analytical sequence includes reagent blanks, calibration verification standards, duplicate preparations, and spiked recovery controls. Because EO dissipates continuously, extraction vials are sealed immediately, and holding times between sample opening and analysis are strictly controlled and documented.

Applications

EO residual determination supports the entire lifecycle of an ethylene oxide sterilization program, from process development to routine market surveillance.

• Sterilization cycle development and validation under ISO 11135, including selection of sterilization temperature, gas concentration, humidity, and exposure time.
• Aeration cycle design and optimization, balancing residual reduction against material stress, product throughput, and energy consumption.
• Establishment of post-sterilization quarantine or release intervals that demonstrate residuals meet ISO 10993-7 limits at the point of distribution.
• Routine batch release testing and periodic verification as part of the manufacturer quality management system.
• Regulatory submissions and conformity documentation for market access in China, Europe, and other jurisdictions.
• Shelf-life and transport simulation studies confirming that residues remain acceptable throughout the labeled storage period.
• Failure investigations, out-of-specification root cause analysis, and evaluation of packaging or supplier changes.

Manufacturers, contract sterilization providers, importers, and distributors all rely on data generated by accredited third-party laboratories to demonstrate that EO-sterilized devices are safe for their intended clinical use.

FAQ

Why is ethylene oxide still used if it is toxic?

EO remains indispensable because it sterilizes at low temperature with deep penetration into lumens, packaging, and complex assemblies that would be damaged by steam, dry heat, or radiation. When sterilization, aeration, and residual testing are properly controlled, the process delivers a high sterility assurance level with residues maintained below biologically safe thresholds.

What is the difference between EO and ECH residuals?

EO is the sterilant itself and dissipates relatively quickly during aeration, whereas ECH is formed when EO reacts with chlorides and can persist longer in aqueous or chloride-containing environments. Both must be quantified because each has its own tolerable exposure limit under ISO 10993-7.

When should residual testing be performed after sterilization?

Testing should reflect the worst-case patient exposure scenario, which means sampling at the earliest point at which the product could be released and used. Since residuals decline continuously during aeration and storage, testing too late can overstate product safety.

Can packaging affect the test result?

Yes. Breathable packaging accelerates dissipation during aeration, while dense or impermeable packaging slows it and can trap residuals. Samples must stay sealed in their original packaging until analysis, otherwise volatile EO will be lost and the result will be artificially low.

How can manufacturers reduce EO residuals?

Effective measures include extending aeration time, raising aeration temperature within material limits, improving load configuration and air circulation, selecting lower-absorbing materials, using more breathable packaging, and optimizing the sterilization cycle to minimize unnecessary gas exposure, all verified through residual testing.

Which test report information is essential?

A compliant report should identify the standard applied (ISO 10993-7 or GB/T 16886.7), the extraction method, the analytical technique, results in mg/device or µg/g for EO and ECH, the detection limits, and a clear pass or fail conclusion against the limits for the device exposure category.